NASDAQ:GLSI Greenwich LifeSciences Q4 2025 Earnings Report $24.51 +0.22 (+0.91%) As of 12:56 PM Eastern ProfileEarnings HistoryForecast Greenwich LifeSciences EPS ResultsActual EPSN/AConsensus EPS -$0.33Beat/MissN/AOne Year Ago EPSN/AGreenwich LifeSciences Revenue ResultsActual RevenueN/AExpected Revenue$0.00 millionBeat/MissN/AYoY Revenue GrowthN/AGreenwich LifeSciences Announcement DetailsQuarterQ4 2025Date6/2/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Greenwich LifeSciences Earnings HeadlinesGLSI stock climbs after removing a key overhang – retail turns focus to high-stakes breast cancer trialJune 2 at 1:11 PM | msn.comGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026June 1 at 8:15 AM | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.June 3 at 1:00 AM | Profits Run (Ad)Greenwich LifeSciences, Inc. Provides Update on 2025 Form 10-K Filing and Phase III Clinical Trial ProgressJune 1 at 6:31 AM | quiverquant.comQGreenwich LifeSciences Provides Update Regarding Form 10-K FilingJune 1 at 6:00 AM | globenewswire.comGreenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingMay 23, 2026 | finanznachrichten.deSee More Greenwich LifeSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email. Email Address About Greenwich LifeSciencesGreenwich LifeSciences (NASDAQ:GLSI) (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies. Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States. The company leverages proprietary technologies to identify immune-modulating compounds and works with contract research organizations to support its preclinical and clinical programs. Greenwich LifeSciences pursues strategic collaborations and licensing arrangements to expand its scientific expertise and accelerate the progress of its therapeutic candidates. With a focus on unmet medical needs in oncology and inflammatory disorders, the company aims to bring first-in-class or best-in-class treatments to patients through disciplined clinical development and regulatory strategies.View Greenwich LifeSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Urban Outfitters Stock Stalls Despite Another Strong QuarterHIVE Earnings Highlight AI Ambitions Beyond Bitcoin MiningMongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared QuarterCredo Technologies Paved a Path to a $300 Price PointFirstCash Turns Pawn Into a Growth Machine Upcoming Earnings Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
